Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
20 mai 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
16 mai 2024 06h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
15 mai 2024 16h01 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
13 mai 2024 16h01 HE
|
Journey Medical Corporation
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7%...
Merkel Cell Carcinoma Treatment Market To Reach USD 4.3 Billion By 2032 | DataHorizzon Research
11 mai 2024 03h40 HE
|
DataHorizzon Research
Fort Collins, Colorado, May 11, 2024 (GLOBE NEWSWIRE) -- The rise in skin disorders aggravates the need for merkel cell carcinoma treatment industry. The merkel cell carcinoma treatment market is...
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
09 mai 2024 16h15 HE
|
AnaptysBio, Inc.
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b...
Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold
09 mai 2024 16h05 HE
|
Sensus Healthcare, Inc.
Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year...
Psoriasis Vulgaris Clinical Trial Pipeline Analysis Demonstrates 50+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
09 mai 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, May 09, 2024 (GLOBE NEWSWIRE) -- Psoriasis Vulgaris Clinical Trial Pipeline Analysis Demonstrates 50+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm,...
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
09 mai 2024 08h30 HE
|
Quoin Pharmaceuticals, Inc.
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into...
Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding
08 mai 2024 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to...